Abstract
While Amyloid-plaques and Tau-tangles are the well-recognized pathologies of Alzheimer’s disease (AD), they are more often observed in healthy individuals than in AD patients. This discrepancy makes it extremely challenging to utilize these two proteinopathies as reliable biomarkers for the early detection as well as later diagnosis of AD. Using the recent advancements in the imaging technology, our newly developed quantification methods, and publicly available neuroimaging data from 303 individuals, we hypothesize and provide preliminary evidence that topographically overlapping Aβ and Tau within the DMN play more critical roles in the underlying pathophysiology of AD than the Tau and/or Aβ pathologies. We first showed that the probability of observing overlapping Aβ and Tau is significantly higher within the DMN than outside DMN. Then we showed evidence that using Aβ and Tau overlap can increase the reliability of the prediction of healthy individuals converting to MCI and a lesser degree converting from MCI to AD. These findings shed some light on the complex pathophysiology of AD and suggest that overlapping Aβ and Tau pathologies within DMN might be a more reliable biomarker of AD for early detection and later diagnosis of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Data used in this paper were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://ADNI.loni.usc.edu). The investigators within the ADNI, who can be found at http://ADNI.loni.usc.edu/study-design/ongoing-investigations, contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or the writing of this article. Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health Grant U01AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; Bio Clinical, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neuro track Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/ or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained in accordance with US 21 CFR 50.25, the TriCouncil Policy Statement: Ethical Conduct of Research Involving Humans and the Health Canada and ICH Good Clinical Practice. Applicable HIPAA privacy notifications was implemented and HIPAA authorizations signed before protocol procedures were carried out. Information was given in both oral and written form as deemed appropriate by the site IRB. Patient confidentiality was strictly held in trust by the participating investigators and research staff. This confidentiality was extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. All data will be transmitted securely via the Internet to ATRI at USC. Access is granted to study team members based on role. Each user of the system has an individual account with a password which is required to be reset at set intervals. Users are logged out of the system after a period of inactivity. All communication to and from the data system is encrypted. Data transmission will occur through a secure internet connection-https (hypertext transfer protocol secured) at 128-bit SSL. The study protocol, documentation, data and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party, without prior written approval of the sponsoring institution. Authorized representatives of the sponsoring institution may inspect all documents and records required to be maintained by the Site PI including but not limited to, medical records (office, clinic or hospital) and pharmacy records for the participants in this study. The clinical study site will permit access to such records. Any data, specimens, forms, reports, and other records that leave the site will be identified only by a participant identification number (Participant ID, PTID) to maintain confidentiality. All records will be kept in a locked file cabinet. All computer entry and networking programs will be done using PTIDs only. Information will not be released without written permission of the participant, except as necessary for monitoring by IRB, the FDA, the NIA, and the OHRP. Information about study participants will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). All ADNI data are shared without embargo through the LONI Image and Data Archive (IDA), a secure research data repository. Interested scientists may obtain access to ADNI imaging, clinical, genomic, and biomarker data for the purposes of scientific investigation, teaching, or planning clinical research studies. Access is contingent on adherence to the ADNI Data Use Agreement and the publications policies outlined in the documents listed below. Note: documents are subject to updates by ADNI. The application process includes acceptance of the Data Use Agreement and submission of an online application form. The application must include the investigators institutional affiliation and the proposed uses of the ADNI data. ADNI data may not be used for commercial products or redistributed in any way. an email confirmation, stating that data access is given by ADNI to Hani Hojjati, the first author, is attached as an added manuscript file.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in this paper were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://ADNI.loni.usc.edu). The investigators within the ADNI, who can be found at http://ADNI.loni.usc.edu/study-design/ongoing-investigations, contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or the writing of this article.